Cancer
Conditions
Keywords
Pediatrics, Brain Tumors, Medulloblastoma, Ependymoma, Atypical teratoid rhabdoid tumor (ATRT), Pineoblastoma, Germ cell tumors (CNS and non-CNS), Neuroblastoma, Osteosarcoma, Ewing's Sarcoma, Rhabdomyosarcoma, Wilms Tumors, Soft Tissue Sarcomas, Langerhans cell histiocytosis (LCH), Histiocytic disorders, Rare pediatric solid tumors, Carcinomas
Brief summary
This study aims to determine the efficacy of daily sirolimus and celecoxib, with low dose etoposide alternating with cyclophosphamide for pediatric participants with relapsed or refractory tumors.
Detailed description
This study aims to learn if the combination of oral sirolimus once daily with celecoxib, and with oral etoposide alternating every 21 days with oral cyclophosphamide (metronomic chemotherapy) is effective in shrinking relapsed or refractory tumors in pediatric participants. In addition, this study seeks to learn the length of time this combination can keep the tumor from growing, learn more about the side effects of sirolimus when used in this combination, and to learn if the sirolimus is working by evaluating blood and tumor tissue.
Interventions
DRUGSirolimus
The starting dose for sirolimus is 2 mg/m2 once daily. The dose of sirolimus will be individually adjusted to achieve a target serum trough concentration in the range of 10-15 ng/ml. Sirolimus will be given by mouth every day for six weeks (every six weeks is called one cycle) for up to two years or 16 cycles.
DRUGCelecoxib
Celecoxib 100 mg will be given by mouth twice a day for six weeks (every six weeks is called one cycle) for up to two years or 16 cycles.
DRUGEtoposide
Etoposide 50 mg/m2 (maximum dose 100 mg) will be given daily by mouth for the first 3 weeks of a 6 week cycle. Six week cycles will be repeated for up to two years or 16 cycles.
DRUGCyclophosphamide
Cyclophosphamide 2.5 mg/Kg (maximum dose 100 mg) will be given daily by mouth for the second 3 weeks of a 6 week cycle. Six week cycles will be repeated for up to two years or 16 cycles.
Sponsors
Emory University
Cannonball Kids' Cancer Foundation
Hyundai Hope On Wheels
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
12 Months to 30 Years
Healthy volunteers
No
Inclusion criteria
* Participants with any of the following tumors who have experienced relapse following front-line therapy, or who are refractory to front-line therapy, and participants with tumors that carry a poor prognosis and have no known standard curative therapy * Brain tumors of all World Health Organization (WHO) grades, except diffuse intrinsic pontine glioma (DIPG) - enrollment in the brain tumor stratum is closed * Extracranial solid tumors including histiocytoses * Participants must have had a histologic verification of malignancy at original diagnosis or relapse, except in participants with optic pathway gliomas, or participants with pineal tumors and elevations of serum or cerebrospinal fluid (CSF) alpha-fetoprotein (AFP) or beta-human chorionic gonadotropin (beta-HCG) * Tissue blocks or slides must be sent * Participants must have radiographically measurable disease at the time of study enrollment to be eligible. Patients with neuroblastoma who do not have measurable disease but have metaiodobenzylguanidine (MIBG+) evaluable disease are eligible. Measurable disease in patients with CNS involvement is defined as tumor that is measurable (≥ 10 mm) in two perpendicular diameters on MRI and visible on more than one slice. For all patients, tumors that are located in a previously irradiated area may be considered measurable if the lesion has shown tumor growth after radiation or has been biopsied and proven to have active disease. * Participant's current disease state must be one for which there is no known curative therapy * Karnofsky performance level of greater than or equal to 50 percent for participants who are greater than 16 years of age at the time of screening * Lansky performance level of greater than or equal to 50 percent for participants who are less than or equal to 16 years of age at the time of screening * Fully recovered from acute toxic effects of all prior anti-cancer therapy * Adequate bone marrow function as deemed by the protocol at the time of screening * Adequate renal function as deemed by the study protocol at the time of screening * Adequate liver function as deemed by the study protocol at the time of screening * Serum triglyceride level ≤300 mg/dL and serum cholesterol ≤ 300 mg/dL * Random or fasting blood glucose within the upper normal limits for age * Adequate pulmonary function as deemed by the study protocol at the time of screening
Exclusion criteria
* Women who are currently pregnant or breastfeeding * Receiving corticosteroids who have not been on a stable dose for at least 7 days * Currently receiving enzyme inducing anticonvulsants * Currently receiving receiving potent CYP3A4 (enzyme) inducers or inhibitors * Currently receiving another investigational drug * Currently receiving any other anti-cancer agents * The use of cannabis oil is prohibited during the first 2 cycles of this protocol. Patients must be off of cannabis oil for 3 days prior to enrollment. * Uncontrolled infection * Participants who in the opinion of the investigator may not be able to comply with the safety monitoring requirements
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Radiographic response to treatment for solid tumors | Baseline, End of Treatment (Up to 2 years) | Radiographic response to treatment will be assessed by Response Evaluation Criteria in Solid Tumors (RECIST) for participants with solid tumors via CT or MRI scan. A complete response (CR) is a disappearance of all target and non-target lesions. Partial response (PR) is at least a 30% decrease in the disease measurement compared to the baseline measurement. Stable disease (SD) is neither sufficient shrinkage to qualify for partial response (PR) nor sufficient increase to qualify for progressive disease (PD) taking as reference the smallest disease measurement since baseline. Progressive disease (PD) is at least a 20% increase in the disease measurement compared to baseline, or the appearance of one or more new lesions, or evidence of laboratory or clinical progression. |
| Radiographic response to treatment for central nervous system (CNS) tumors | Baseline, End of Treatment (Up to 2 years) | Radiographic response to treatment will be assessed for participants with CNS tumors via CT or MRI scan. Response criteria are assessed based on the lesion of the longest diameter and its longest perpendicular diameter. Development of new disease or progression in any established lesions is considered progressive disease, regardless of response in other lesions. Complete response (CR) is the the disappearance of all target lesions. Partial response (PR) is greater than or equal to 50% decrease decrease in the sum of the products of the two perpendicular diameters of all target lesions, taking into reference the baseline measurement. Stable disease (SD) is neither a sufficient decrease in the sum of the products of the two perpendicular diameters of all target lesions to qualify for PR, nor sufficient increase in a single target lesion to qualify for progressive disease (PD). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of adverse events | Baseline, End of Treatment (Up to 2 years) | The adverse events associated with sirolimus in combination with metronomic chemotherapy administered on this schedule will be defined and evaluated throughout the treatment period. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORThomas Cash, MD
Emory University
Outcome results
None listed